SI1423105T1 - Kombinacija DMXAA in drugih sredstev proti raku - Google Patents

Kombinacija DMXAA in drugih sredstev proti raku

Info

Publication number
SI1423105T1
SI1423105T1 SI200230798T SI200230798T SI1423105T1 SI 1423105 T1 SI1423105 T1 SI 1423105T1 SI 200230798 T SI200230798 T SI 200230798T SI 200230798 T SI200230798 T SI 200230798T SI 1423105 T1 SI1423105 T1 SI 1423105T1
Authority
SI
Slovenia
Prior art keywords
dmxaa
combination
combinations
cancer agents
topoisomerase
Prior art date
Application number
SI200230798T
Other languages
English (en)
Slovenian (sl)
Inventor
William Robert Wilson
Bronwyn Gae Siim
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Publication of SI1423105T1 publication Critical patent/SI1423105T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pyrane Compounds (AREA)
SI200230798T 2001-09-03 2002-09-03 Kombinacija DMXAA in drugih sredstev proti raku SI1423105T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0121285.1A GB0121285D0 (en) 2001-09-03 2001-09-03 Anti-cancer combinations
PCT/GB2002/004025 WO2003020259A2 (en) 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents
EP02758562A EP1423105B9 (en) 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents

Publications (1)

Publication Number Publication Date
SI1423105T1 true SI1423105T1 (sl) 2009-08-31

Family

ID=9921418

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200230798T SI1423105T1 (sl) 2001-09-03 2002-09-03 Kombinacija DMXAA in drugih sredstev proti raku

Country Status (23)

Country Link
US (6) US7863322B2 (enExample)
EP (3) EP1423105B9 (enExample)
JP (3) JP2005509599A (enExample)
CN (5) CN100536840C (enExample)
AT (1) ATE415963T1 (enExample)
AU (1) AU2002324143B2 (enExample)
BR (1) BR0212258A (enExample)
CA (1) CA2458459A1 (enExample)
CY (1) CY1110426T1 (enExample)
DE (1) DE60230159D1 (enExample)
DK (1) DK1423105T3 (enExample)
EA (3) EA200801611A1 (enExample)
ES (1) ES2321283T3 (enExample)
GB (1) GB0121285D0 (enExample)
IL (1) IL160178A0 (enExample)
IS (1) IS7144A (enExample)
MX (1) MXPA04002004A (enExample)
NO (1) NO20040591L (enExample)
NZ (5) NZ531045A (enExample)
PT (1) PT1423105E (enExample)
SI (1) SI1423105T1 (enExample)
WO (1) WO2003020259A2 (enExample)
ZA (1) ZA200401078B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
ATE324888T1 (de) * 1999-06-14 2006-06-15 Cancer Rec Tech Ltd Krebstherapie
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
SI1689404T1 (sl) 2003-11-13 2009-02-28 Pharma Mar Sau Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
GB0517387D0 (en) * 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
WO2007023302A1 (en) * 2005-08-26 2007-03-01 Antisoma Plc Combinations comprising dmxaa for the treatment of cancer
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
CN101896177A (zh) * 2007-12-13 2010-11-24 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
CN101279967B (zh) * 2008-05-29 2010-11-10 武汉远大制药集团有限公司 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途
CN102203132A (zh) * 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
WO2011019782A1 (en) * 2009-08-11 2011-02-17 Novartis Ag Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
DK2582847T3 (en) 2010-06-18 2016-12-19 Myriad Genetics Inc METHODS AND MATERIALS TO ASSESS loss of heterozygosity
ES2588979T3 (es) 2010-08-24 2016-11-08 Dana-Farber Cancer Institute, Inc. Procedimientos para la predicción de una respuesta contra el cáncer
CN102786509B (zh) * 2011-05-16 2016-06-01 杭州民生药业有限公司 2-(5,6-二甲基呫吨酮-4-基)-乙酸的衍生物及其制备方法和用途
CA2839210A1 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
AU2012358244A1 (en) 2011-12-21 2014-06-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
EP2617421A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
CA3080441A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
ES2777228T3 (es) 2013-04-05 2020-08-04 Myriad Genetics Inc Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer
WO2014169067A1 (en) * 2013-04-09 2014-10-16 Merrimack Pharmaceuticals, Inc. Compositions for improving outcomes of liposomal chemotherapy
JP2016538344A (ja) * 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CA2958801A1 (en) 2014-08-15 2016-02-18 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
CN115282140B (zh) * 2022-02-07 2024-03-08 南京市儿童医院 Aki治疗剂及dmxaa在制备该治疗剂中的应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015265A1 (de) 1969-03-29 1970-10-08 Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) Arylalkansäuren und Verfahren zu deren Herstellung
US3655470A (en) * 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
US4565806A (en) * 1981-08-18 1986-01-21 Setaelae Kai M E Composition and method for rational treatment of cancer
FR2516922A1 (fr) * 1981-11-25 1983-05-27 Lipha Acides (oxo-4-4h-(1)-benzopyran-8-yl) alcanoiques, sels et derives, preparation et medicament les contenant
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
US4704355A (en) * 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
ES2061518T3 (es) 1986-12-23 1994-12-16 Warner Lambert Co Compuestos que tienen propiedades antitumorales y antibacterianas.
JPH01193227A (ja) 1988-01-29 1989-08-03 Res Dev Corp Of Japan 癌免疫療法補助剤
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5075287A (en) 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5250296A (en) 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB9308166D0 (en) * 1993-04-20 1993-06-02 Cancer Res Campaign Tech Cancer therapy
GB9320484D0 (en) 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
DE4417742A1 (de) * 1994-05-20 1995-11-23 Bayer Ag Nicht-systemische Bekämpfung von Parasiten
US5620875A (en) * 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
WO1996032418A1 (en) 1995-04-13 1996-10-17 Laboratoires Om S.A. Anti-cd14 antibodies for use in the induction of il-10 secretion
EP0743064A1 (en) 1995-05-17 1996-11-20 Eli Lilly And Company Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease
JPH0940690A (ja) 1995-05-23 1997-02-10 Yutaka Sashita ステロイド配糖体及びこれを有効成分とする医薬
WO1997004761A1 (en) 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
US5977077A (en) 1995-08-28 1999-11-02 Interlab Corporation Xanthone analogs for the treatment of infectious diseases
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
WO2000015176A2 (en) 1998-09-10 2000-03-23 Magainin Pharmaceuticals, Inc. Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
UA47505C2 (uk) 1996-12-13 2002-07-15 Елі Ліллі Енд Компані Спосіб лікування плоскоклітинного раку ротової порожнини за допомогою антагоністів лейкотриєну
JP2001509143A (ja) 1996-12-13 2001-07-10 イーライ・リリー・アンド・カンパニー 大脳病巣性卒中のためのロイコトリエンアンタゴニスト
AU5792398A (en) 1996-12-13 1998-07-03 Eli Lilly And Company Leukotriene antagonists for treatment or inhibition of gout
DE69815310T2 (de) 1997-03-11 2004-04-22 Les Laboratoires Aeterna Inc. Zubereitungen zur tumorbehandlung enthaltend hai-knorpelextrakte und antineoplastische mittel
HUP9904672A2 (hu) 1997-03-21 2000-05-28 Eli Lilly And Co. Szájüregi laphámrák ellen alkalmazható leukotrién antagonisták
AU6450498A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating gout
AU6570798A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating gingivitis
US5998454A (en) 1997-03-21 1999-12-07 Eli Lilly And Company Leukotriene antagonists useful for treating iritis
WO1998042345A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating cerebral focal stroke
AU6572298A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
AU6764798A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating cystic fibrosis
US5914340A (en) 1997-03-21 1999-06-22 Eli Lilly And Company Leukotriene antagonists useful for treating dermatoses
DE19721211A1 (de) 1997-05-21 1998-11-26 Lindner Sen Wolfgang Dr Med Kombination von antientzündlichen Wirkstoffen mit immunstimulierenden Agentien und zytotoxischen Agentien zur Behandlung von Tumoren
IL141627A0 (en) 1998-08-24 2002-03-10 Maxim Pharm Inc Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US6174873B1 (en) * 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
ATE289586T1 (de) * 1999-03-01 2005-03-15 Pfizer Prod Inc Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
ATE324888T1 (de) 1999-06-14 2006-06-15 Cancer Rec Tech Ltd Krebstherapie
US6806257B1 (en) * 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
AU778829B2 (en) 1999-11-11 2004-12-23 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EP1231939A2 (en) 1999-11-11 2002-08-21 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
EP1259237A4 (en) * 2000-02-17 2004-07-28 Merck & Co Inc TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS
JP2001247459A (ja) * 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
JP2004505047A (ja) * 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
GT200500186A (es) * 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
WO2007023302A1 (en) 2005-08-26 2007-03-01 Antisoma Plc Combinations comprising dmxaa for the treatment of cancer
GB0517387D0 (en) 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
MX2010003594A (es) 2007-10-23 2010-09-22 Antisoma Res Ltd Formas cristalinas de sal sodica de dmxaa.

Also Published As

Publication number Publication date
CN100536840C (zh) 2009-09-09
CN1994287A (zh) 2007-07-11
BR0212258A (pt) 2004-10-19
US20040204480A1 (en) 2004-10-14
US7863320B2 (en) 2011-01-04
EA008056B1 (ru) 2007-02-27
WO2003020259A2 (en) 2003-03-13
EP1423105B9 (en) 2009-08-12
JP2010270124A (ja) 2010-12-02
DE60230159D1 (de) 2009-01-15
CN101596186A (zh) 2009-12-09
US20070060637A1 (en) 2007-03-15
EA200601118A1 (ru) 2006-12-29
US20080070886A1 (en) 2008-03-20
US7863322B2 (en) 2011-01-04
CN101607087A (zh) 2009-12-23
US7863321B2 (en) 2011-01-04
ES2321283T3 (es) 2009-06-04
EP2236134A1 (en) 2010-10-06
NZ576925A (en) 2010-07-30
NZ531045A (en) 2006-08-31
IL160178A0 (en) 2004-07-25
CA2458459A1 (en) 2003-03-13
NZ546573A (en) 2007-05-31
JP2005509599A (ja) 2005-04-14
JP2009263371A (ja) 2009-11-12
CN1708296A (zh) 2005-12-14
ZA200401078B (en) 2005-04-15
EP1759694A2 (en) 2007-03-07
US20080070848A1 (en) 2008-03-20
NZ567456A (en) 2009-08-28
EP1423105B1 (en) 2008-12-03
NO20040591L (no) 2004-04-30
US20080070847A1 (en) 2008-03-20
NZ554093A (en) 2008-07-31
AU2002324143B2 (en) 2007-09-13
US7868039B2 (en) 2011-01-11
US20080070849A1 (en) 2008-03-20
MXPA04002004A (es) 2005-02-17
ATE415963T1 (de) 2008-12-15
EA200801611A1 (ru) 2009-06-30
US7868040B2 (en) 2011-01-11
WO2003020259A3 (en) 2003-04-17
EP1423105A2 (en) 2004-06-02
CY1110426T1 (el) 2015-04-29
DK1423105T3 (da) 2009-03-30
EP1759694A3 (en) 2009-02-18
GB0121285D0 (en) 2001-10-24
EA200400370A1 (ru) 2004-08-26
CN101596187A (zh) 2009-12-09
EA010857B1 (ru) 2008-12-30
IS7144A (is) 2004-02-06
PT1423105E (pt) 2009-03-09

Similar Documents

Publication Publication Date Title
SI1423105T1 (sl) Kombinacija DMXAA in drugih sredstev proti raku
ATE400274T1 (de) Hemmstoffe der akt aktivität
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
ECSP003610A (es) Pirimidina-2,4,6 trionas inhibidores de metaloproteinas
DE69911798D1 (de) Bicyclische piperidin- und piperazin-verbindungen mit 5-ht6-rezeptor-affinität
BR0008453A (pt) Composição sinergìstica anti-tumoral
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
ATE446752T1 (de) Hemmer der akt aktivität
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
BR0116115A (pt) Derivados de carboxamida e seu uso no tratamento de doenças tromboembólicas e tumores
PA8543201A1 (es) DERIVADOS DE DIHIDRO-BENZO [B] [1,4]-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGluR2
DK0583421T3 (da) Substituerede dibenzoxazepinforbindelser, lægemidler og fremgangsmåder til anvendelse
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
BR0116481A (pt) Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6
HRPK20030734B3 (en) A combination comprising combretastatin and anticancer agents
BRPI0417007A (pt) agentes antivirais de diazaindol-dicarbonil-piperazinila
BR0311970A (pt) Novos compostos, seu uso e preparação
BRPI0412554A (pt) pirazolinas como antagonistas par-1 para o tratamento de doenças distúrbios cardiovascular
BR0000901A (pt) Derivados 4-fenil-4-heteroarilpiperidina
DE69823650D1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
ATE412411T1 (de) Pmcol zur behandlung von prostatakrebs
ATE311228T1 (de) Antikrebs-kombinationen aus dmxaa und paclitaxel oder docetaxel
ATE279182T1 (de) Verwendung spezieller verbindungen zur prophylaxe und therapie von hepatitis c
ES8207542A1 (es) Un procedimiento para la preparacion de 1rs,4rs,5rs-4-(4,8 dimetil-5-hidroxi-7-nomen-1-1-il)-4-metil-3,8-dioxabiciclo(3.2.1)octano-1.aletico.
DK1200099T3 (da) Synergistisk sammensætning indeholdende daunorubicinderivater og antimetabolitforbindelser